SpringWorks Therapeutics, Inc. (SWTX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-Market:
| Previous Close | 46.69 |
| Open | 46.68 |
| Bid | 46.77 x 100 |
| Ask | 46.88 x 200 |
| Day's Range | 45.35 - 48.18 |
| 52 Week Range | 18.00 - 53.92 |
| Volume | |
| Avg. Volume | 1,161,716 |
| Market Cap | 3.469B |
| Beta (5Y Monthly) | 0.82 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GuruFocus.com
SpringWorks Therapeutics Inc (SWTX) Reports Q4 and Full Year 2023 Financial Results
R&D Expenses: R&D expenses increased to $150.5 million in 2023, reflecting investment in clinical trials and drug development. Net Loss: Net loss widened to $325.1 million in 2023, with a loss per share of $5.15.
- GuruFocus.com
SpringWorks Therapeutics Inc Insider Sells Company Shares
Chief Commercial Officer Bhavesh Ashar has executed a sale of 8,056 shares of SpringWorks Therapeutics Inc (NASDAQ:SWTX) on February 5, 2024, according to a recent SEC filing.
- GuruFocus.com
SpringWorks Therapeutics Inc Chief People Officer Daniel Pichl Sells 26,181 Shares
Daniel Pichl, Chief People Officer of SpringWorks Therapeutics Inc (NASDAQ:SWTX), executed a sale of 26,181 shares in the company on February 2, 2024, according to a recent SEC Filing.
© 2024 Yahoo. All rights reserved.